An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes

用于 1 型糖尿病早期诊断和改进治疗的超灵敏、高通量和低成本自身免疫组合

基本信息

  • 批准号:
    9559575
  • 负责人:
  • 金额:
    $ 74.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

Type 1 diabetes (T1D) is a devastating autoimmune disease that destroys islet-cell insulin production. Millions of Americans, especially children, are affected and must rely on lifelong insulin administration and struggle with life-threatening co-morbidities. Most new cases of T1D are diagnosed in emergency settings with presentation in potentially deadly diabetic ketoacidosis (DKA). Current pre-clinical diagnostic tests that can permit preventive action for T1D are slow and not readily available outside of tertiary care centers. In this proposal Enable Biosciences will further develop and validate a novel low-cost and high-throughput immunoassay to rapidly and sensitively screen for the four cardinal autoantibody markers that predict risk for type 1 diabetes. Such a test could supplant the current expensive, slow radioactive method. By reducing costs while retaining sensitivity and specificity with a robust very low-sample volume assay, Enable Biosciences' product will permit increased testing to reveal incipient T1D in the general population at the optimal time for intervention. During the Phase I funding period, Enable prototyped a 3-member T1D autoantibody panel using their core Antibody Detection by Agglutination-PCR (ADAP) technology and demonstrated substantial equivalence with the gold-standard assay while removing reliance on radioactive reagents. In this Phase 2 proposal, Enable presents a comprehensive plan to enhance this panel via automation using a dedicated robotic liquid handling system, greatly increasing assay throughput and reliability while further reducing costs. We will also adapt our assay chemistry to be able to use Taqman probes. This will result in further throughput acceleration and cost reductions. Building upon promising preliminary results from Phase 1 work, we will incorporate the fourth and final T1D autoantibody (ZnT8) to create the world's first ever “4-in-1” screening panel, creating a product that provides the highest level of risk assessment for T1D screening and diagnosis. These optimized and automated panels will then be rigorously validated with thousands of clinical samples provided by our wide network of enthusiastic academic and institutional partners that include the Joslin Diabetes Center, Stanford School of Medicine, the T1D Exchange and Tufts Children's Hospital. This data will be used to plan and direct commercialization efforts that will include a phased approach from delivering a CLIA-certified laboratory service to FDA-approved reagent kits with companion integrated sample-to-answer hardware devices for easy, low-skill use and deployment across research and clinical laboratories and screening sites worldwide.
1型糖尿病(T1D)是一种破坏性的自身免疫性疾病,破坏胰岛细胞胰岛素的产生。数以百万计的美国人,特别是儿童,受到影响,必须终身依赖胰岛素治疗,并与危及生命的合并症作斗争。大多数T1D新病例是在紧急情况下诊断的,表现为潜在致命的糖尿病酮症酸中毒(DKA)。目前可以对T1D采取预防行动的临床前诊断测试速度缓慢,而且在三级保健中心之外不易获得。在这项提案中,Enable Biosciences将进一步开发和验证一种新的低成本、高通量的免疫测定方法,以快速、灵敏地筛选预测1型糖尿病风险的四种主要自身抗体标记物。这样的测试可以取代目前昂贵、缓慢的放射性方法。通过降低成本,同时保持极低样本量检测的灵敏度和特异性,Enable Biosciences的产品将允许增加检测,在最佳干预时间发现普通人群中的早期T1D。在I期融资期间,Enable利用其核心抗体检测技术ADAP (Antibody Detection by Agglutination-PCR)制作了一个3成员T1D自身抗体面板的原型,并证明了与金标准分析的基本等效性,同时消除了对放射性试剂的依赖。在第二阶段提案中,Enable提出了一个全面的计划,通过使用专用机器人液体处理系统的自动化来增强该面板,大大提高了分析通量和可靠性,同时进一步降低了成本。我们还将调整我们的分析化学,以便能够使用Taqman探针。这将导致进一步的吞吐量加速和成本降低。基于第一阶段工作的初步结果,我们将纳入第四种也是最后一种T1D自身抗体(ZnT8),以创建世界上第一个“4合1”筛查面板,创建一个为T1D筛查和诊断提供最高水平风险评估的产品。这些优化和自动化的面板将通过我们广泛的热情的学术和机构合作伙伴网络提供的数千个临床样本进行严格验证,这些合作伙伴包括乔斯林糖尿病中心,斯坦福医学院,T1D交流和塔夫茨儿童医院。这些数据将用于规划和指导商业化工作,包括分阶段的方法,从提供clia认证的实验室服务到fda批准的试剂盒,以及配套的样品到答案的集成硬件设备,以便在全球的研究和临床实验室和筛选地点轻松,低技能地使用和部署。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Seftel其他文献

David Seftel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Seftel', 18)}}的其他基金

Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk
开发自动化高通量干血斑测定法以促进大规模筛查 1 型糖尿病风险
  • 批准号:
    10020787
  • 财政年份:
    2019
  • 资助金额:
    $ 74.98万
  • 项目类别:
Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk
开发自动化高通量干血斑测定法以促进大规模筛查 1 型糖尿病风险
  • 批准号:
    9910015
  • 财政年份:
    2019
  • 资助金额:
    $ 74.98万
  • 项目类别:
Multiplex food allergy diagnostic based on IgE immunologic markers
基于 IgE 免疫标记物的多重食物过敏诊断
  • 批准号:
    10011621
  • 财政年份:
    2018
  • 资助金额:
    $ 74.98万
  • 项目类别:
Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance
利用自我收集的毛细血管干血点推进易于使用、高通量和多重胰岛自身抗体测试,以供监管审批
  • 批准号:
    10699934
  • 财政年份:
    2016
  • 资助金额:
    $ 74.98万
  • 项目类别:
Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring
凝集 PCR 抗体检测 (ADAP):一种用于 T1D 诊断和监测的超灵敏、高通量、可多重工具
  • 批准号:
    9185244
  • 财政年份:
    2016
  • 资助金额:
    $ 74.98万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了